Trade the Jaguar Health share!
JAGUAR HEALTH

Analysis before buying or selling Jaguar Health shares

Trade the Jaguar Health share!
BUY   SELL
68% of retail CFD accounts lose money - eToro.com
 
Chart provided by Tradingview

Are you considering trading Jaguar Health shares online or buying the stock as part of your portfolio? If so, you need to make sure you have all the information you need to analyze it. In this article, we offer you data about this company and its economic environment, such as details of its activities and sources of income, its main competitors and partners on the market, and elements to follow as part of your fundamental analysis of this stock.

Elements to consider before selling or buying Jaguar Health shares

Analysis N°1

We will have to keep an eye on the various research and development projects carried out by the group with the aim of diversifying its product portfolio and thus reaching a wider audience.

Analysis N°2

Jaguar Health's collaborations with other companies, particularly in the pharmaceutical sector, will also require your attention, and we will be watching with interest for strategic research and marketing partnerships.

Analysis N°3

Of course, you will also need to look at the Jaguar Health Group's direct competitors and their activities and developments in order to anticipate changes in the distribution of market share.

Analysis N°4

It will be important to keep an eye on the Jaguar Health Group's development strategy and communications to its shareholders regarding strategic developments and growth objectives.

Analysis N°5

Finally, it is also important to take note of the company's quarterly and annual results and compare them with the targets set and analysts' expectations.

68% of retail CFD accounts lose money. This is an advert for trading CFDs on eToro

General presentation of Jaguar Health

In order to help you perform good analysis of Jaguar Health stock, we now offer a detailed presentation of this company. It is essential to understand how this company generates revenue in order to anticipate any changes in its growth over the long term.

Jaguar Health Inc. is an American company operating in the pharmaceutical sector. More specifically, the company specializes in the natural products segment.

In more detail, Jaguar Health specializes in the development and sale of new, sustainably derived gastrointestinal products for both humans with prescription drugs and animals. These products are marketed worldwide.

In addition, through its subsidiary Napo Pharmaceuticals Inc., the group focuses on the development and commercialization of gastrointestinal pharmaceuticals for humans and the global market. These products are based on plants that are traditionally used in tropical forest areas.

Among the leading products developed by the group is Mytesi, an antidiarrheal prescribed to relieve the symptoms of non-infectious diarrhea in adult patients suffering from HIV or Human Immunodeficiency Virus or AIDS or Acquired Immune Deficiency Syndrome and on antiretroviral therapy. Its product portfolio also includes treatments such as Canalevia, Equilevia, Neonorm Calf and Neonorm Foal.

The group currently employs 34 people.

Analysis before buying or selling Jaguar Health shares
68% of retail CFD accounts lose money. This is an advert for trading CFDs on eToro

The major competitors of Jaguar Health

Now that you are more familiar with the Jaguar Health Group's activities, we would like to tell you more about its industry environment, including an overview of its main competitors in the sector.

GW Pharmaceuticals

This British pharmaceutical company is listed on the Nasdaq as well as the London Stock Exchange and is a laboratory that has a license in England for the development of medicines based on cannabinoid medicine. Currently, it is one of the leading producers of medical cannabis in the world.

Lexicon Pharmaceuticals Inc

This company is a biopharmaceutical company that develops treatments for human diseases. Specifically, the group has advanced several drug candidates into human clinical trials and has a large and diverse pipeline of drug targets behind its clinical programs. The group is pursuing drug targets in 5 major therapeutic areas including oncology, gastroenterology, immunology, metabolism and ophthalmology.

Anatara Lifesciences

Finally, the Anatara Lifesciences group is an Australian company specialising in the development of oral solutions for gastrointestinal diseases in livestock and humans, but also develops and markets a non-antibiotic therapy to prevent and treat diarrhoea in piglets. A similar version of this treatment is also being developed for humans. The group collaborates with various pharmaceutical and biotechnology companies for the clinical development and sale of products for human and animal applications.


The major partners of Jaguar Health

Jaguar Health has many enemies in its industry, but fortunately it has some strategic allies to help boost profitability and growth. Here is a specific example of a strategic partnership that Jaguar Health has recently put in place:

Knight Therapeutics

In 2018, the group notably teamed up with Knight Therapeutics, a pharmaceutical company in Canada specializing in the acquisition, licensing, sale and marketing of innovative prescription and over-the-counter pharmaceutical products. The agreement is a distribution, licensing and supply agreement providing Knight with the exclusive right to market Mytesi and related products in the Canadian and Israeli markets and the right of first negotiation for the marketing of Mytesi and related products in certain Latin American countries. Mytesi has been approved by the FDA in the United States and is indicated for the relief of symptoms of non-infectious diarrhea in adult HIV/AIDS patients on antiretroviral therapy. Jaguar is following up on potential follow-on indications for this treatment in cancer treatment-related diarrhea, rare diseases of infants and children with congenital diarrhea disorders and short bowel syndrome, as well as for irritable bowel syndrome or IBS and as a supportive treatment for inflammatory bowel disease or as a second-generation antisecretory agent for patients treated for cholera.

68% of retail CFD accounts lose money. This is an advert for trading CFDs on eToro

Frequently Asked Questions

What analysis should you use to anticipate changes in Jaguar Health stock?

While there are different types of analysis that investors use to try to anticipate changes in the Jaguar Health share price, it is important not to settle for just one, but to increase your chances of getting good signals by using several analyses together, such as technical analysis and fundamental analysis, and to compare the indications obtained by these two methods.

How do you make a coherent financial analysis of Jaguar Health?

Among the analyses that it is important to carry out before trading the Jaguar Health share, one finds in particular the financial analysis. This analysis is based on the study of the group's financial results but also and above all on their evolution over time as well as on the comparison of these actual results with the analysts' forecasts and the objectives possibly fixed by the group itself in the framework of its strategy. These results can be found on the Jaguar Health website.

Is it possible to trade Jaguar Health shares on the downside?

While most stock market investment products from banks and brokers today do not allow you to short Jaguar Health shares, you can still trade the stock down using derivatives such as CFDs or contracts for difference. These contracts replicate the price of the stock and allow you to take both a buy and sell position.

eToro is a multi-asset platform which offers both investing in stocks and cryptoassets, as well as trading CFDs.

Please note that CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 68% of retail CFD accounts lose money. You should consider whether you can afford to take the high risk of losing your money.

Past performance is not an indication of future results. Trading history presented is less than 5 complete years and may not suffice as basis for investment decision.

Copy trading is a portfolio management service, provided by eToro (Europe) Ltd., which is authorised and regulated by the Cyprus Securities and Exchange Commission.

Cryptoasset investing is unregulated in some EU countries and the UK. No consumer protection. Your capital is at risk.

eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro.